SCHEMBL19435487

SCHEMBL19435487

CC(C)(C)OC(=O)C(C)(C)Sc1ccc2cnsc2c1-c1cccnc1

nearest known ligand 0.53

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 15/20 0.53
GBA1 P04062 1/20 0.35
DUSP10 Q9Y6W6 1/20 0.35
RAB9A P51151 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
GPR119 Q8TDV5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23129667 0.91 SLC22A12 (0.54) SLC22A12CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL17899887 0.87 SLC22A12 (0.69) SLC22A12
SCHEMBL19435490 0.84 SLC22A12 (0.62) SLC22A12
SCHEMBL19435498 0.83 SLC22A12 (0.77) SLC22A12RAB9A
SCHEMBL19562883 0.82 SLC22A12 (0.49) SLC22A12CYP1A2CYP3A4CYP2C9
SCHEMBL19435510 0.82 SLC22A12 (0.79) SLC22A12
SCHEMBL19435464 0.82 SLC22A12 (0.61) SLC22A12RAB9A
SCHEMBL19435472 0.82 SLC22A12 (0.77) SLC22A12
SCHEMBL19435527 0.80 SLC22A12 (0.60) SLC22A12GPR119
SCHEMBL19435474 0.77 SLC22A12 (0.48) SLC22A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3241822-B1 URAT1 INHIBITOR NIPPON CHEMIPHAR CO (JP) 2021-03-24 EP claimed
CN-107108478-B URAT1 inhibitors 日本化学药品株式会社 2020-04-24 CN claimed
US-10173990-B2 URAT1 inhibitor NIPPON CHEMIPHAR CO., LTD. (JP) 2019-01-08 US claimed
EP-3241822-A1 URAT1 INHIBITOR Nippon Chemiphar Co., Ltd. (JP) 2017-11-08 EP claimed
US-20170290795-A1 URAT1 INHIBITOR J-PHARMA CO., LTD. (JP) 2017-10-12 US claimed
EP-3241822-B1 URAT1 INHIBITOR NIPPON CHEMIPHAR CO (JP) 2021-03-24 EP disclosed
CN-107108478-B URAT1 inhibitors 日本化学药品株式会社 2020-04-24 CN disclosed
US-10173990-B2 URAT1 inhibitor NIPPON CHEMIPHAR CO., LTD. (JP) 2019-01-08 US disclosed
EP-3241822-A1 URAT1 INHIBITOR Nippon Chemiphar Co., Ltd. (JP) 2017-11-08 EP disclosed
US-20170290795-A1 URAT1 INHIBITOR J-PHARMA CO., LTD. (JP) 2017-10-12 US disclosed
US-20170290795-A1 URAT1 INHIBITOR J-PHARMA CO., LTD. (JP) 2017-10-12 US disclosed
US-20170290795-A1 URAT1 INHIBITOR J-PHARMA CO., LTD. (JP) 2017-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170290795-A1 URAT1 INHIBITOR SLC10A1, XDH, URB2 SLC22A12 512/4885GBA1 658/4885DUSP10 1179/4885
US-10173990-B2 URAT1 inhibitor SLC10A1, XDH, URB2 SLC22A12 500/4885GBA1 617/4885DUSP10 1146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.